Diabetic Macular Edema
Conditions
Keywords
KH902, Diabetic macular Edema, Intravitreal injection, Multiple injections, 20 patients, 0.5mg/eye/time
Brief summary
This study is designed to access the safety and efficacy of multiple injections of KH902 in patients with Diabetic Macular Edema (DME).
Detailed description
With improvement of our living standard, patients who suffered from Diabetes become more and more. As the investigators know, Diabetes can induce many ocular diseases leading to vision loss. And according to observations, DME is diagnosed as one main cause of vision loss in the patients with Diabetes. As the results of many studies conducted previously, anti-VEGF drugs and anti-VEGF treatments show its effect and safety not only in treating AMD, but also in patients with DME. The new drug Recombinant Human VEGF Receptor-Fc Fusion Protein (KH902) is a gene fusion protein. The previous clinical trials of KH902 show that KH902 is effective and safe in inhibiting the growth, migration, pullulation of vascular endothelial cells and neovascularization induced by VEGF. Due to these positive results, the investigators prepare to conduct a clinical trial to assess the safety and efficacy with intravitreal injection of KH902 in patients with DME.
Interventions
BIOLOGICALKH902
Intravitreal injection of 0.5mg/eye/time KH902
Sponsors
University of Wisconsin, Madison
Teaching and Research Office of Health Statistics, Fourth Military Medical University
Chengdu Kanghong Biotech Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Signed the Informed Consent Form and willing to comply with study procedures; * 18 years old ≦ either gender ≦ 75 years old; * Confirmed diagnosed with Type 1 diabetes or Type 2 diabetes based on the diabetes diagnosis criteria; * Clinically significant DME: * Hard exudation within 500μm of the central foveal diameter accompanied with contiguous retina thickening; * The edema locates within 500μm of the central foveal diameter; * Retina thickening field \> 1DD and within the 1DD central fovea. * BCVA score of the study eyes between 78 and 19 letters, inclusively, and the BCVA score of fellow eyes ≥ 24 letters; * Previous treatment of antidiabetic drugs within three months preceding the screening, and blood-glucose concentration is predicted to be unchanged and stable during the whole study.
Exclusion criteria
* Uncontrolled glaucoma in either eye; * Currently active ocular inflammation or infection in either eye; * Macular edema in the study eye was caused by other diseases rather than diabetes; * Company with any other ocular conditions failing to prevent vision loss despite improving the macular edema; * Any other ocular diseases which may cause macular edema or vision alteration during study phase; * Retinal macular traction or macular epiretinal membrane in study eye; * Refractive error equate or exceed 8 diopters of myopia in study eye * Whole or regional retinal laser photocoagulation has been applied in study eye within 6 months preceding the screening; * Previous anti-VEGF drug treatment in study eye; * Intraocular or periocular injection of steroid drug within 6 months preceding the screening; * Previous ophthalmologic operation within 3 months preceding the screening and/or planning to receive an ophthalmologic operation during the study. * There is any potential for the study eye to receive the panretinal laser photocoagulation treatment during the study; * Previous vitrectomy in study eye. * Uncontrolled diabetes; * Hypertensive patients with poorly controlled blood pressure; * Uncontrolled systemic infectious diseases; * Systemic immune diseases; * History of allergy; * Any uncontrolled clinical disorders; * Pregnant or nursing women; * Adopt one or more adequate contraception methods.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence rate of adverse event | up to 12 months | To evaluate the safety of multiple intravitreal injection of KH902 to treat DME. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from Baseline in BCVA | at the end of month 3 and the end of month 12 | To evaluate the efficacy of multiple intravitreal injection of KH902 of each group. |
Countries
China
Outcome results
None listed